English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Early and accurate diagnosis of movement disorders and dementia is critically important to ensure patients receive appropriate treatment. Ioflupane I123 injection (ioflupane (123I) or (123I) FP-CIT or DaTscanTM or DaTscanTM) is approved in Europe and the US for diagnostic use only, for detecting loss of functional dopaminergic neuron terminals in the striatum in patients with clinically uncertain parkinsonian syndromes (PS), including those at an early stage, to help differentiate essential tremor (ET) from PS related to Parkinson’s disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP). (Figure 1) Ioflupane (123I) is unable to discriminate between PD, MSA, and PSP. In Europe, Ioflupane (123I) is also approving to help differentiate probable dementia with Lewy bodies (DLB) from Alzheimer’s disease (AD). Ioflupane (123I) is not able to discriminate between dementia with Lewy bodies and Parkinson’s disease dementia (Table 1).

Ioflupane I123 Injection (DaTscanTM) SPECT Brain Imaging in Patients with Movement Disorders and/or Dementia: Preliminary Report